Copyright
©The Author(s) 2018.
World J Clin Cases. Aug 16, 2018; 6(8): 161-166
Published online Aug 16, 2018. doi: 10.12998/wjcc.v6.i8.161
Published online Aug 16, 2018. doi: 10.12998/wjcc.v6.i8.161
Table 1 Biologics approved for the management of gastrointestinal inflammatory and oncological conditions
| Condition/disease | Biologic | FDA approved biosimilar |
| Crohn’s disease | Infliximab (anti-TNFα) | Remsima, Inflectra, Renflexis, Flixabi |
| Adalimumab (anti-TNFα) | Amjevita, Cyltezo | |
| Certolizumab (anti-TNFα) | NA | |
| Vedolizumab (anti-α4-integrin) | NA | |
| Natalizumab (anti-α4-integrin) | NA | |
| Ustekinumab (anti-IL-antibody) | NA | |
| Ulcerative colitis | Infliximab (anti-TNFα) | Remsima, Inflectra, Renflexis, Flixabi |
| Adalimumab (anti-TNFα) | Amjevita, Cyltezo | |
| Golimumab (anti-TNFα) | NA | |
| Colorectal cancer | Bevacizumab (anti-VEGF) | Mvasi |
| Ramucirumab (anti-VEGF) | NA | |
| Cetuximab (anti-EGFR) | NA | |
| Pantimumab (anti-EGFR) | NA | |
| Gastric cancer | Trastuzumab (anti-HER2/neu) | Ogivri |
- Citation: Kaida-Yip F, Deshpande K, Saran T, Vyas D. Biosimilars: Review of current applications, obstacles, and their future in medicine. World J Clin Cases 2018; 6(8): 161-166
- URL: https://www.wjgnet.com/2307-8960/full/v6/i8/161.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v6.i8.161